Clinical Trial Update: Effect of Telitacicept on Antibody Titers in Primary APS Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the effect of Telitacicept on antibody titers in patients with primary antiphospholipid syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Syndrome

Drugs mentioned

• Telitacicept

Snippet

Sponsor: Ruijin Hospital | Conditions: Antiphospholipid Syndrome (APS) | Phase 2 | Status: COMPLETED